Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

12 Dec 2016

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.

Maribavir as good as valganciclovir for cytomegalovirus infection in transplant recipients

5 days ago

Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus (CMV) viraemia in transplant recipients, a study has found.

The phase II, open-label trial randomized 161 recipients of haematopoietic-cell or solid-organ transplants with CMV reactivation (1,000 to 100,000 DNA copies per millilitre) to receive maribavir at a dose of 400, 800 or 1,200 mg twice daily or the standard dose of valganciclovir for no more than 12 weeks.

Of the patients, 159 received treatment and 156 had postbaseline data available (117 in the maribavir groups and 39 in the valganciclovir group). Response to treatment within 3 weeks occurred in 62 percent of patients in the combined maribavir groups and 56 percent in the valganciclovir group. Within 6 weeks of treatment, 79 percent and 67 percent of patients had a response (risk ratio, 1.20, 95 percent confidence interval, 0.95–1.51). Treatment response did not differ among the maribavir dose groups.

CMV infection recurred within 6 weeks in two patients who received maribavir at a dose of 800 mg twice daily. Both patients developed T409M resistance mutations in CMV UL97 protein kinase.

Serious adverse events that occurred or worsened during treatment were higher in the maribavir group than in the valganciclovir group (44 percent vs 32 percent). Adverse events leading to trial discontinuation also occurred with greater frequency in the former (23 percent vs 12 percent). Gastrointestinal adverse events were common with maribavir, whereas neutropaenia was reported more frequently with valganciclovir.

Maribavir, especially given its unique mechanism of action and evidence suggesting a lack of myelosuppression, should be explored further in patients who have undergone transplantation, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

12 Dec 2016

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.